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Abstract
Polycyclic aromatic hydrocarbons (PAH) are 
widely distributed in the environment, and 
some are carcinogenic to human beings. The 
study of biomarkers has helped clarify the na-
ture and magnitude of the human health risks 
posed by such substances. This article provides a 
review of the state-of-the-art on PAH biomark-
ers for human health risk assessment and also 
discusses their applicability within the context 
of environmental management in Brazil. The 
article discusses the methodologies for determi-
nation of some biomarkers such as 1-hydroxypy-
rene and PAH-DNA adducts. Cytogenetic mark-
ers, frequency of chromosomal aberrations, and 
micronucleus induction were considered for the 
evaluation of cancer risk. The current stage of 
studies on validation of such biomarkers was 
also approached.
Aromatic Polycyclic Hydrocarbons; Biological 
Markers; Risk Assessment
Introduction
Knowledge of human health risks related to en-
vironmental exposure to hazardous chemical 
agents is a current concern. The majority of situ-
ations involve exposures to low doses for long pe-
riods, which in many cases involve the individu-
al’s entire lifetime and result in small increments 
in health risks.
In environmental exposures, traditional epi-
demiological approaches evaluating mortality 
and morbidity indicators display the following 
limiting factors: non-specificity of biological ef-
fects; latency time between exposure and mag-
nitude of the effect, principally for carcinogenic 
effects; and limitations of epidemiological stud-
ies for detecting small risk increments.
Thus, other methods have been investigated 
to better detect associations between conditions 
of exposure to toxic agents and human health 
risks. Among these, biomarkers have been con-
sidered promising and have received the great-
est attention in studying populations exposed 
to chemical contaminants. The World Health 
Organization (WHO) 1 defines biomarker as any 
substance, structure, or process that can be mea-
sured within an organism or its products and 
influences or predicts the incidence of harmful 
effects or disease.
Biomarkers can be measured after exposure 
to food, environmental, or occupational sources 
to elucidate dose-effect relations in risk assess-
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ment, clinical diagnosis, and other forms of mon-
itoring 2.
Biomarkers are classified in three catego-
ries: (i) biomarkers of exposure, which involve 
detection and measurement of an exogenous 
substance, metabolite, or product of interaction 
between the xenobiotic and some molecule or 
target cell; (ii) biomarkers of effect, including 
measurement of biochemical and physiological 
alterations that can be related to the occurrence 
of disease or harm to health; and (iii) biomarkers 
of susceptibility, indicative of an organism’s in-
herent or acquired ability to respond to the chal-
lenge of exposure to xenobiotics.
The integrated application of epidemiological 
studies, environmental behavior of contaminants, 
and biomarkers can provide more solid data in 
relation to the human health risks resulting from 
environmental exposure to chemical substances 
like polycyclic aromatic hydrocarbons (PAH). 
The widespread distribution of PAH in the envi-
ronment associated with various human activi-
ties, especially burning of fossil fuels, has raised 
concerns over the impacts of health exposures, 
especially in urban areas. Some PAH are now rec-
ognized as carcinogens or probable carcinogens 
for human beings and other mammals. Recent 
studies demonstrate that PAH with more than 
three aromatic rings account for 70-90% of the 
total carcinogenic effect related to these sources, 
thus posing a serious health threat 3.
Investigation of the sequence of events be-
ginning with exposure to potentially harmful 
substances and culminating with the increase in 
morbidity and mortality events is a challenge for 
public health research. In this context, the use of 
biomarkers is a promising approach.
However, research on biomarkers has still not 
reached these objectives. According to Bonassi et 
al. 4, confusing and sometimes conflicting results 
have been obtained from studies on the exposed 
population. In this sense, it has only proven pos-
sible to intervene successfully in the develop-
ment of disease or to increase the capacity to de-
tect low doses of given substances or mixtures of 
different agents in some specific situations.
The recognition of these limitations and the 
need for prior validation of biomarkers before 
their application motivated the current study, 
the objective of which was to characterize the 
state of the art in studies on PAH biomarkers in 
settings involving environmental exposure and 
the current requirements for validation, aimed 
at backing the use of these biomarkers in envi-
ronmental risk assessment. We also conducted a 
critical analysis of the applicability of biomarkers 
for risk assessment in the context of environmen-
tal management in Brazil.
Methodology
The material for this review was obtained from 
the Electronic Reference Library (ERL), using 
WebSPIRS from SilverPlatter Information (Ovid 
Technologies, New York, USA; http://www.ovid.
com/site/products/tools/silverplatter/sp_web
spirs.jsp?top=2&mid=3&bottom=8&subsection
=14).
To select the most relevant databases for the 
study subject, we conducted a search for the free 
term (biomarker* OR biological marker*) AND 
(polycyclic aromatic hydrocarbon). This survey 
allowed us to verify which databases contained 
articles on the respective subject. The selected 
databases were: MEDLINE, Biological Abstracts, 
Aquatic Sciences and Fisheries Abstracts (ASFA), 
Zoological Records, and CAB Abstracts. A total of 
423 articles were found in these databases, dis-
tributed as follows: 151 articles in PubMed On-
line, 108 in MEDLINE, 96 in Biological Abstracts, 
33 in ASFA, 22 in Zoological Records, and 13 CAB 
Abstracts.
Of all the articles located, we selected those 
published from 1995 to 2005 that approached 
the use of biomarkers for the assessment of PAH 
effects, with special emphasis on articles that 
presented previously validated methodologies 
and those aimed at validating new methodolo-
gies and approaches. Other articles not directly 
related to the specified theme were discarded. 
Some articles prior to the specified period were 
included because they were considered relevant 
to the subject under discussion. To determine the 
study’s relevance and decide on its inclusion or 
exclusion, the available abstracts were read, and 
after selection of the studies directly related to the 
theme, a search was made for the full texts, which 
were then considered in the present review.
After obtaining the full texts, the analysis 
phase was performed, consisting of grouping the 
information on the available types of PAH bio-
markers and verifying the situation of the studies 
conducted until the time of the review.
Human exposure to PAH
PAH are binary substances formed by carbon and 
hydrogen and constituting a subclass of polycy-
clic aromatic compounds (PACs); the latter are 
organic compounds containing two or more 
fused aromatic rings, that can be arranged in a 
straight line, angled, or in clusters. As an overall 
characteristic, this class of compounds presents 
low vapor pressure and high melting and boiling 
points and very limited solubility in water, which 
tends to decrease with the increase in molecular 
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mass. Environmentally relevant sources of PAH 
are: smoking, fossil fuel combustion, vehicle ex-
haust, and use of lubricant oils. PAH are used as 
intermediate substances in the production of 
plasticizers, pigments, drying agents, and pes-
ticides, but the environment probably receives 
only small amounts as a direct result of these ac-
tivities; the most significant emissions are from 
incomplete combustion of organic materials 
during industrial processes and other anthropo-
genic activities 5.
There are more than different 100 PAH, gen-
erally present in complex mixtures and not as 
a single substance 6, of which 16 are classified 
by the U. S. Environmental Protection Agency 
as priority pollutants for environmental inves-
tigation: acenaphthene, acenaphthylene, an-
thracene, benzo[a]anthracene, benzo[a]pyrene, 
benzo[b]fluoranthene, benzo[g,h,i]perylene, 
benzo[k]fluoranthene, chrysene, dibenzo[a,h] 
anthracene, phenanthrene, fluoranthene, fluo-
rene, indeno[1,2,3-c,d]pyrene, naphthalene, and 
pyrene 6.
According to the U.S. Agency for Toxic Sub-
stances & Disease Registry (ATSDR) 7, background 
atmospheric values of some representative PAH 
vary from 0.02 to 1.2ng/m3 in rural areas and 0.15 
to 19.3ng/m3 in urban areas. In countries like 
Italy and Germany, reference values vary from 1 
to 10ng/m3, frequently exceeded in urban areas. 
In Brazil, there are also studies on environmental 
levels in some urban areas 8,9,10.
Human exposure can occur in indoor or out-
door environments and by all routes (inhalation, 
ingestion, and skin contact), regardless of the 
source. PAH formed by burning of fossil fuels, 
smoke from forest fires, and cigarette smoking 
are mainly available for inhalation, but they can 
also be ingested together with food (e.g., smoked 
foods, atmospheric deposition on vegetables, 
and coal used for cooking) or saliva (smoking). 
For skin contact, the principal primary sources 
are exposure to tar, soot, and organic solvents 11.
In the human body, since PAH are lipophilic 
substances, they are readily dissolved and trans-
ported by cell membrane lipoproteins. The ab-
sorption rate depends on the specific PAH 12. 
In general, they are distributed throughout the 
body and found in any internal organ or tissue, 
particularly in lipid-rich tissues and the gastro-
intestinal tract, through the reabsorption of the 
product of hepatobiliary excretion 5.
Experimental animal studies have demon-
strated that some PAH cause tumors in case of 
oral or cutaneous exposure. In food exposure, ef-
fects have been found in the reproductive system 
related to fertility, problems during pregnancy, 
and congenital anomalies 7. Epidemiological 
studies have also shown the relevant role of PAH 
in carcinogenesis 3,13.
PAH biomarkers
Advances in analytical theories allow measur-
ing increasingly lower concentrations of chemi-
cal substances in the environment. Meanwhile, 
epidemiological studies face difficulties in estab-
lishing correlations between these exposures and 
effects on human health. In such situations, the 
sensitivity of biomarkers allows detection and 
measurement at reduced concentrations, thus 
expanding the reach of dose-response studies for 
assessing sub-lethal effects 1,14.
The quantity of substances monitored de-
pends on the medium sampled, the objectives, 
and the available resources. Exposures are gen-
erally proportional to the PAH concentrations in 
the environment. Environmental assessment of 
PAH mixtures can be based on one that is repre-
sentative of the group, like benzo[a]pyrene or a 
group of PAH – benzo[a]anthracene, chrysene, 
benzo[b]fluoranthene, benzo[k]fluoranthene, 
benzo[a]pyrene, dibenzo[ah]anthracene, benzo 
[ghi]perylene, and indeno[1,2,3-cd]pyrene 15.
After the substance enters the body, the unal-
tered (parental) substance or its metabolites are 
searched for in the urine, blood, feces, or other 
bodily fluids or tissues. Since parental PAH gen-
erally present a reduced plasma half-life, hydrox-
yl metabolites are the most frequent option for 
investigation.
PAH metabolism into more soluble forms is 
a necessary step for their excretion. The parental 
compound is generally oxidized by phase 1 en-
zymes through hydroxylation catalyzed by cyto-
chrome P450 monooxygenase enzymes; hydro-
lysis and reduction can also occur. These phase I 
metabolites bind to glutathione, sulfates, or gluc-
uronic acid to form phase II metabolites in order 
to form more polar and water-soluble substances 
than the original substances, thereby greatly fa-
cilitating their excretion. The metabolites and 
conjugates are excreted via the urine and feces, 
but conjugates excreted in bile can be reabsorbed 
in the intestine. The hydroxyl metabolites can be 
used as biomarkers based on their ability to indi-
cate the internal dose received 3.
The majority of these reactions result in de-
toxification, but compounds can be produced 
that are highly reactive as electrophilic PAH me-
tabolites, which can form covalent interactions 
with proteins and nucleic acid, resulting in ad-
ducts that can compromise normal cell function-
ing, triggering a series of harmful effects 3,5,15.
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Hydroxyl PAH metabolites: biomarkers of 
internal dose
Metabolites excreted in the urine provide more 
appropriate estimates of total ingestion as com-
pared to exposure assessments based on envi-
ronmental data. The choice of the urinary metab-
olite should consider the constituent of the most 
common PAH. In cases of complex mixtures, 
more than one biomarker should be considered 
to ensure adequate evaluation. 1-hydroxypyrene 
is the most widely used metabolite in PAH expo-
sure, since pyrene is one of the most abundant 
hydrocarbons in all PAH mixtures and has as its 
principal metabolite 1-hydroxypyrene formed 
in mammals 3,16,17, thus representing a sensitive 
biomarker of exposure, recommended by various 
authors as the most relevant parameter in esti-
mates of individual exposure to PAH 1,17,18,19,20,21. 
Smoking is monitored with cotinine (a hydroxyl 
metabolite of nicotine), which allows controlling 
this intervening variable in studies on environ-
mental PAH exposure 3,15.
Human monitoring studies describe the half-
life of urine 1-hydroxypyrene as varying from 4 
to 48 hours, and the time between exposure and 
sample collection is an important factor. In en-
vironmental exposures, 24-hour urine samples 
express the best correlation with concentrations. 
Since environmental concentrations can vary, it 
is necessary to characterize the exposure pattern 
for each situation and study population, by iden-
tifying the environmental pyrene concentrations 
and background 1-hydroxypyrene 15,17 values, 
measured in a reference group.
PAH-DNA: biomarkers of effective dose
PAH play an undeniable role in the induction of 
human carcinogenesis. There is evidence on the 
transformation of healthy cells into cancer cells, 
using in vitro cell culture experiments, animal 
studies, and in vivo studies with occupationally 
or environmentally exposed healthy human vol-
unteers and cancer patients 9.
Chemical induction of carcinogenesis is a 
complex process; multiple stages involve muta-
tions in cell growth-regulating genes (proto-on-
cogenes) and tumor-suppressor genes 13,15,22.
DNA adducts have proven to be promising 
biomarkers, since they consider individual differ-
ences in exposure, absorption, and distribution 
of chemical agents, metabolism to DNA-reactive 
forms, detoxification in reactive intermediaries, 
and cell replacement and repair of DNA damage. 
DNA adducts are used to assess both exposure 
and cancer risk in humans.
However, use in humans is limited by ethi-
cal issues, since most target organs for PAH-in-
duced carcinogenesis are not accessible by rou-
tine sample; therefore, studies used surrogate 
tissues, with easily obtained cells like circulating 
leukocytes 13. However, this practice has been 
criticized, since surrogate cells are not always 
targets for PAH or the most sensitive for the for-
mation of adducts, thus potentially compromis-
ing the reliability of in vivo studies. Conflicting 
results have been found in relation to the forma-
tion of PAH-DNA adducts in leukocytes. Some 
studies on occupational exposure indicate the 
occurrence of these adducts in unexposed indi-
viduals as well 13,23; studies in groups of smokers 
failed to show significant alteration in compari-
son to the control group, suggesting a source 
other than smoking 13,24; other studies show that 
dermal exposure and ingestion of PAH may be 
more significant than inhalation in the forma-
tion of adducts in circulating leukocytes 13,25.
An evaluation of different leukocytes sub-
populations is necessary for the correct interpre-
tation of the contribution of the exposure routes 
involved, to minimize difficulties in correlating 
adduct levels in target organs and those observed 
in circulating cells. Phillips et al. 24 failed to show a 
relationship between DNA adducts in leukocytes 
and lung cells. Other more recent studies only 
indicate a correlation with mononuclear cells, 
showing that adducts in leukocyte cell fractions 
may reflect adduct levels in relevant target organs 
and be used to monitor and evaluate cancer risk. 
The life span of lymphocytes (days to year) may 
qualify these cells for evaluating long-term expo-
sures, while monocytes and granulocytes (hours 
and days) only represent more recent exposures, 
thus compromising estimates of adducts in total 
leukocytes. It is thus necessary to intensify char-
acterization studies involving leukocytes in order 
to generate detailed information on the above-
mentioned conflicting data.
Other cells have been used, like alveolar mac-
rophages, cells obtained from bronchoalveolar 
lavage 26, easily obtained by sputum induction, 
an easily applicable and relatively non-invasive 
technique 27. The highest DNA adduct levels were 
observed, respectively, in: alveolar cells, circulat-
ing mononuclear monocytes, and granulocytes, 
suggesting that measuring adducts in these first 
two cells allows a more sensitive analysis in the 
evaluation of exposures to inhaled PAH 13.
The relationship between PAH exposure and 
formation of adducts has been used to assess the 
applicability of DNA adducts to distinguish be-
tween two or more exposure levels 13, aimed at 
providing the basis as an ancillary methodology 
for exposure estimates.
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Studies in animals show a strong dose-re-
sponse relationship in exposures to low doses, 
which is not always found in humans. Lung tissue 
from smokers showed a correlation between ad-
duct levels and number of cigarettes per day, but 
the dose-response curve tends to level off at high 
doses (> 20 cigarettes/day) 28. Different individu-
als exposed to similar levels present variations in 
the levels of adducts formed, probably due to the 
genetic polymorphism in the enzymes involved 
in the activation or detoxification of PAH and the 
DNA repair mechanism. This variation accounts 
for differences in susceptibility to the develop-
ment of cancers; various studies have focused 
on the identification of the genes responsible for 
such differences 13,29,30. Variations are also ob-
served within and between individuals and are 
related mainly to intermittence in the exposure 
pattern, in addition to action by other inter-
vening factors such as: smoking, differences in 
eating patterns, and seasonal differences in the 
bioavailability of the substances. Thus, intra and 
inter-individual variations must be characterized 
before applying PAH-DNA adducts as markers of 
exposure in large-scale studies 13,29,30,31.
Cytogenetic alterations: biomarkers 
of early effect
In cell cultures of peripheral lymphocytes, cy-
togenetic alterations like chromosomal aberra-
tions, sister chromatid exchange, and micronu-
cleus induction have been applied as biomarkers 
of exposure and early effect in exposures to geno-
toxic carcinogens 30,32.
Like the majority of biomarkers for geno-
toxicity, cytogenetic alterations in lymphocytes 
are estimates obtained from surrogate tissues, 
presuming that they represent more specific 
chromosomal alterations, important in the car-
cinogenesis of target tissues. Evidence has been 
found in studies showing the high frequency of 
chromosomal aberrations, but not chromatid 
exchange or micronucleus induction in periph-
eral lymphocytes as predictive parameters of in-
creased cancer risk 15,30,33,34.
The relevance of increased frequency of cyto-
genetic alterations as biomarkers of cancer risk 
has been corroborated by epidemiological stud-
ies suggesting the high frequency of chromosom-
al aberrations as the best predictive parameter 
for increased cancer risk.
Genetic polymorphism: biomarkers 
of susceptibility
Genetic polymorphisms have received increas-
ing attention, since they can modulate the hu-
man response to exposures to genotoxic agents, 
whose role in susceptibility can be studied more 
easily through the use of biomarkers like cytoge-
netic alterations 30,35,36.
Studies on genetic polymorphism depend 
on: the biological material examined and the ex-
posure and ethnic composition of the study pop-
ulation. Since cytogenetic markers can represent 
exposures that occurred months before the tissue 
sampling, simple measurements of urinary me-
tabolites or environmental concentrations may 
not be representative of the most relevant expo-
sure period. For different exposure levels, the ex-
posed individuals should be grouped in distinct 
categories and compared to the control group to 
allow distinguishing exposure-genotype interac-
tions from background biomarker levels 30.
Another important factor is the expression 
of genotype differences in the cell or tissue ex-
amined. As an example, the enzymes glutathi-
one-s-transferase M1 (GSTM1) and T1 (GSTT1) 
detoxify various reactive chemical agents and 
are expressed in leukocytes and erythrocytes 30. 
Individuals that possess at least one copy for the 
alleles GSTM1 A or GSTM1 B possess GSTM1 ac-
tivity, but homozygotes for the deletion of the 
GSTM1 gene (GSTM1-null genotype) do not 
present this activity 37. The frequency of the 
GSTM1-null genotype is approximately 50% 
in the Caucasian population 36. Likewise, the 
homozygous deletion of gene GSTT1 (GSTT1-
null genotype), found in 13-28% of Caucasians, 
makes them unable to perform GSTT1-mediat-
ed detoxification 30,37. Consequently, high rates 
of cytogenetic damage induced by genotoxic 
substances can be expected in cells of GSTM1 
and T1-null individuals, which totally lose their 
respective enzymatic activities 30.
Knudsen et al. 38 observed that GSTM1-null 
bus drivers (non-smokers) exposed to urban air 
pollution show a high frequency of chromosomal 
aberrations as compared to GSTM1-positive driv-
ers. Other studies of DAN adducts have suggested 
that the GSTM1-null DNA genotype predisposes 
carriers to increased genotoxic effects from PAH-
polluted air 30,39,40,41. Such studies observed that 
the frequency of micronucleus induction in lym-
phocytes only correlates with the level of DNA 
adducts in GSTM1-null individuals.
Many of the monooxygenase enzymes – cyto-
chrome P450 – are polymorphic, and some geno-
types are associated with high enzymatic activity, 
so that high induction is expected when exposed 
to chemical agents. The principal variant al-
leles in the cytochrome P450 1A gene (CYP1A1) 
include alleles 2A, 2C, 2B, and 4 42. Studies are 
limited on the effect of cytochrome P450 poly-
morphism on chromosomal damage, and their 
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interpretation is complicated by the limited clar-
ity of associations between the cytochrome P450 
genotype and the phenotypical expression of rare 
variant alleles 30.
High levels of chromosomal aberrations in 
peripheral lymphocytes have been observed for 
the prediction of increased cancer risk for smok-
ing and occupational exposure. Various poly-
morphisms in enzymes for the metabolism of 
xenobiotics have indicated an inductive effect on 
cytogenetic biomarkers 30.
The importance of various genetic polymor-
phisms in determining the level of cytogenetic 
alterations depends on the following factors: cy-
togenetic parameter, chemical agent, and ethnic 
composition of the study population. Cytogenet-
ic biomarkers can be used to identify sub-groups 
that are sensitive to carcinogens.
Validation
Validation of a biomarker is a set of necessary 
procedures for reliable extrapolation, to real 
conditions, of data obtained under experimen-
tal conditions. According to the WHO 1, validity 
refers to the biomarker’s accuracy; it is a complex 
characteristic that describes the extent to which 
the biomarker reflects a specific event in a bio-
logical system.
A biomarker can only be used systematically 
after experimental and epidemiological valida-
tion 1,43. In experimental research, validity refers 
to the nature of the biomarker and the assay’s 
necessary characteristics for the determination 
of its levels, presence, and/or activity, as well as 
to the essay’s sensitivity for detecting response 
at a known concentration and specificity for a 
given particular event. Epidemiological studies 
use experimental validity data as the basis for 
studies in human populations; they also examine 
their feasibility for use in humans, sensitivity and 
specificity for population groups, and the assay’s 
reliability under field conditions.
Bonassi et al. 4 presented a general proposal 
for validation of biomarkers for human health 
risk assessment, consisting of three interdepen-
dent phases: development of the biomarker, 
characterization, and longitudinal studies.
During the development phase of the bio-
marker, parameters are evaluated for perform-
ing the assay: stability, reliability, sensitivity, and 
specificity, in addition to adequate procedures 
for collecting and preserving samples 1,44,45,46.
Characterization of the biomarker exam-
ines its variability in population subgroups and 
measures the impact of potential confounders 
in the association between biomarker and bio-
logical event. Longitudinal studies evaluate the 
relationship between frequency of the biomarker 
and disease incidence, based on observational 
studies 4.
Development of biomarkers is facilitated 
when data from observational studies of humans 
are linked to experimental studies with animals 
and in vitro cell lines 1.
Application of biomarkers to 
environmental risk assessment
Until recently, damage to health resulting from 
environmental factors was mainly identified on 
the basis of retrospective studies 47,48,49 based on 
responses to acute events like accidents and oc-
cupational exposures.
However, chronic exposures rarely result in 
rapid and easily observable change. The impact 
is almost always gradual and subtle, and it fre-
quently becomes difficult to distinguish between 
natural environmental changes and impacts from 
other sources; the time scale for such events is on 
the order of decades, thus making retrospective 
studies complicated 49.
In this sense, increasing efforts have focused 
on risk assessment studies based on models and 
data for environmental concentrations of the 
contaminants, a tool already widely adopted in 
various countries. Environmental risk assess-
ment is understood as consisting of four stages: 
identification of hazards; evaluation of exposure; 
dose-response assessment; and risk character-
ization 50. Such studies are based on information 
from experimental toxicity studies and physical 
and chemical characteristics of the substances 
and their behavior in the environment.
The main advantages of risk assessment are: 
low cost, lack of need for population interven-
tions; and possibility for use in the assessment of 
postulated exposure settings, not depending on 
the existence of real situations of human expo-
sure. However, they are heavily dependent on the 
existence of toxicological data and models that 
are not always reliable, especially for low doses, 
and they do not adequately assess exposure to 
mixtures of contaminants in fluctuating condi-
tions prevailing in the environment 50.
Recent studies on human exposure to envi-
ronmental contaminants have incorporated lab-
oratory analytical techniques into epidemiologi-
cal inventories to elucidate the biochemical or 
molecular basis for the etiology of diseases, thus 
providing useful information like internal dose 
and biological effects, using biomarkers 51.
Evaluation of chromosomal aberrations and 
micronucleus induction as intermediate param-
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eters in cross-sectional studies to assess DNA 
damage can provide insights on mechanisms 
in the exposure-disease relationship, to supple-
ment evidence (even though non-conclusive) of 
carcinogenicity. They can also evaluate whether 
chromosomal damage is related to new expo-
sures that do not present sufficient time to be 
evaluated by means of association with cancer 
incidence, based on longitudinal studies 52.
However, caution is needed in interpreting 
these parameters, since a positive association be-
tween exposure and frequencies of chromosomal 
aberrations and micronucleus can be informa-
tive, but null association does not guarantee the 
absence of carcinogenic effect 52.
The advantage of applying biomarkers to 
cross-sectional studies is the possibility of ob-
taining detailed and accurate information on: 
current exposure pattern, possible confounders, 
and specific effects 32,53. However, processing 
blood and urine samples for the analysis of chro-
mosomal aberrations and micronucleus is toil-
some, and the simultaneous evaluation of a large 
number of samples can be problematic 52.
Thus, many studies present relatively small 
samples (n < 100 individuals), thereby compro-
mising studies of exposures at low doses, which 
require larger samples.
Many samples require complex logistics, in-
cluding cryopreservation of total blood or lym-
phocytes isolated for subsequent analysis, which 
can introduce an adverse effect on the study. 
Hayes et al. 54 demonstrated the recovery of via-
ble lymphocytes from cryopreserved total blood, 
while others have only shown success with the 
cryopreservation of isolated lymphocytes 55. It 
has also been demonstrated that cryopreserva-
tion of samples can induce an increase in chro-
mosomal aberrations and a decrease in cell vi-
ability 56.
The use of chromosomal aberrations and mi-
cronucleus in prospective cohort studies, ade-
quate for validation since they furnish important 
information on causality in the dose-response 
relationship, has been applied in limited fashion, 
mainly to validate evaluation of exposure 52.
While cohort studies have serial sample col-
lection over time as their theoretical advantage, 
in practice very long studies impose limitations 
on sample collection and preservation, thus in-
volving some restrictions. Chromosomal aber-
rations and micronucleus, as well as the prin-
cipal genetic aberrations, only reflect the most 
recent months of exposure, which may not be 
representative for the exposure and/or disease 
under investigation 52. In this case, the study of 
translocations may be more adequate, since they 
are genetic alterations that persist for decades 53.
Cohort studies with chromosomal aberra-
tions and micronucleus as early parameters for 
cancer risk in human populations have been 
performed mainly using the ad hoc method 
52,57. Investigation based on samples obtained 
from several smaller biomonitoring studies are 
limited by differences in the respective analyti-
cal techniques, lack of detailed information on 
confounding, and possible specific effects in the 
sampled populations 52.
Other factors like technological innovation 
and validation of early parameters for cancer pre-
diction are directing the expansion of application 
of cytogenetic biomarkers.
The development of analytical techniques has 
transformed the applications of assays, which are 
currently capable of providing valuable informa-
tion on early stages of chronic diseases, especial-
ly cancer 52.
Likewise, the study of interphase cells has 
transformed the micronucleus assay, not only 
into a rapid and simple test for genotoxicity, but 
as a tool to evaluate important events like gene 
amplification 58.
The most obvious advantages expected in the 
coming years with the use of biomarkers include 
increased reliability in the evaluation of exposure 
and detection of early damage in populations 
exposed to reduced levels or complex mixtures 
of genotoxic agents. The identification of ge-
netic variations linked to chromosomal damage 
is increasing the sensitivity and power of these 
studies, facilitated by the reduction in the costs 
of molecular techniques and increased use of au-
tomation, which will allow studies of large popu-
lations, increasing the sensitivity for detecting 
effects of exposure 52.
Importantly for the validation of cytogenetic 
biomarkers as early parameters for cancer pre-
diction, the causal relationship between chro-
mosomal aberrations and cancer risk has been 
described in cohort studies 59.
In recent years, many international studies 
have focused on the effects of environmental 
pollutants in children, and molecular epidemio-
logical studies have provided new perspectives 
in pediatric populations, increasingly supporting 
the widely known fact that children are more sus-
ceptible than adults to toxic substances 60.
Two recent reviews by Neri et al. 60,61 have 
shown that biomarkers of genetic damage are 
capable of detecting early biological effects in 
exposed children and newborns and are consis-
tently increased in pre and postnatal exposures 
to cigarette smoke, and in postnatal exposures 
to urban air pollution. Thus, these studies sug-
gest that biomonitoring programs benefit from 
including biomarkers.
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The application of cytogenetic biomarkers 
to the prediction of cancer risk in healthy in-
dividuals is a considerable challenge. Uncer-
tainties in risk prediction at the individual level 
and the complexity of ethical issues are factors 
that could delay the design and planning of 
studies 52. Nevertheless, it is already possible 
to use validated biomarkers as instruments for 
prevention policies and programs for charac-
terization of effects in high-risk populations. 
Chromosomal aberrations and micronucleus 
are sufficiently consolidated for application in 
cross-sectional studies, aimed at characterizing 
early carcinogenic effects 52.
The application of cytogenetic biomarkers 
for screening individuals is of the utmost impor-
tance, since it represents the necessary step for 
establishing surveillance programs applicable to 
national regulations for occupational and envi-
ronmental safety 52.
Critical analysis of the application 
of biomarkers for environmental 
management in Brazil
The current approach to environmental man-
agement in Brazil focuses on the identification 
and control of sources of pollution based on their 
compliance with pollutant emissions and envi-
ronmental quality standards. Health is always 
the greater good to be protected, and values and 
standards are always set with a view towards 
guaranteeing adequate levels of protection for 
human and ecosystem health. Brazil still experi-
ences difficulties in defining quality criteria and 
standards compatible with the national reality 
and environmental specificities; the reference 
values are nearly always imported, without a 
more in-depth analysis of their environmental, 
social, and health implications for the Brazilian 
population.
However, recent studies in the United States 
have demonstrated this model’s weakness in re-
lation to the control of human exposures to envi-
ronmental contaminants and reduction of health 
risks. According to Steinemann 62, recent stud-
ies by the USEPA, the Centers for Disease Con-
trol and Prevention (CDC), and the Mount Sinai 
School of Medicine in New York show that per-
sons are more exposed in internal versus external 
environments, due to the significant contribu-
tion of household cleaning and hygiene prod-
ucts. For example, exposure to volatile organic 
compounds (VOCs) in internal environments is 
5-10 times greater than external exposure, even 
in urban areas with high pollution and intense 
industrial activity.
Meanwhile, rates of diseases that may be asso-
ciated with exposure to chemical substances have 
increased significantly in recent years throughout 
the United States. According to Steinemann 62, 
cancer in children increased by 26% from 1975 to 
1999, highlighting acute lymphocytic leukemia 
(62%) and cancers of the central nervous system 
and brain (50%). Testicular cancer in young men 
increased 85% (1973-1999) and is already the 
most common type of cancer among men 15-35 
years of age. According to the American Cancer 
Society, only 5-10% of all cancers can be attrib-
uted to endogenous factors, while the rest are 
caused by environmental factors.
These studies demonstrate the need to redi-
rect the current focus of environmental regula-
tions in the sense of prioritizing not only envi-
ronmental quality control but also the effective 
assessment of human exposure to contaminants. 
In this context, studies of biomarkers gain rel-
evance to the extent that they allow not only ex-
posure assessment but also prediction of effects 
and human health risk.
However, as verified in this study, the use of 
biomarkers in environmental risk assessment 
studies requires prior and reliable databases 
and information, not only to identify the situ-
ations in which the biomarker can contribute 
to the understanding of the exposure-disease 
processes, but also to increase the credibility 
of its results. Although these studies with bio-
markers have generated a significant amount of 
information to back their utilization, consistent 
criteria are necessary concerning the prior char-
acterization of the study area and population 
in order to use them adequately and produce 
reliable results.
Furthermore, studies with biomarkers may 
not be feasible for large or ethically restricted 
populations, since sample collection in humans 
can only be performed with strict compliance to 
ethical principles and with prior informed con-
sent of subjects.
Based on the above, some important consid-
erations are in order from the perspective of us-
ing biomarkers for management of environmen-
tal problems in Brazil:
• Despite advances in environmental manage-
ment, there are still great difficulties to be over-
come, especially in relation to environmental 
information systems in the country. For example, 
air pollution control, even in metropolitan areas, 
only considers the basic indicators, and there 
are no data on environmental concentrations of 
other toxic pollutants. Neither are there reliable 
inventories of industrial installations and pollut-
ant emission levels that could provide the basis 
for identification, through mathematical models, 
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of critical exposure areas, where studies on bio-
markers could be performed;
• In most Brazilian States, there is still no in-
ventory of contaminated areas. In the State of 
São Paulo, which already has a methodology for 
identification/management and a periodically 
updated registry of these areas, little or no in-
formation exists on human exposure there, even 
in the areas have already subjected to remedia-
tion;
• Another relevant aspect is the development 
of closer collaboration between environmental 
and health agencies and the establishment of in-
tegrated information systems to jointly support 
the definition of integrated and more effective 
policies and actions in the interface between 
health and the environment;
• Expansion of the scope of activity by institu-
tions to encompass studies of human exposure 
evidently means not only formal expansion, but 
also an increase in current investments for train-
ing human resources and implementing the nec-
essary infrastructure;
• The use of biomarkers, when compared with 
methods based on the definition of standards, 
can initially be more difficult to apply and entail 
a higher cost. However, measurement of envi-
ronmental concentrations alone does not guar-
antee the absence of adverse effects for human 
health;
• Despite difficulties in the development of 
characterization studies, especially in Brazil 
(with limited resources and infrastructure), the 
possibility of understanding local specificities is 
precisely the greatest advantage of biomarkers, 
constituting an important tool for the evalua-
tion of effectiveness (or lack thereof) in the pre-
vailing standards, allowing the assessment and 
adjustment of their values and providing more 
reliable responses to the human and ecosystem 
health conditions.
Conclusion
Analysis of the recent literature shows that the 
application of biomarkers to environmental risk 
assessment, especially for human health, has ex-
panded continuously thanks to the advances ob-
tained in characterization and validation studies, 
although their utilization depends on consistent 
criteria for defining the study area and popula-
tion. The limited number of studies published in 
Brazil, including the reviews by Lopes et al. 63 and 
Pereira Netto et al. 64, indicate the need for greater 
incentives and institutional support to foster the 
use of this approach in the national context.
For assessing human exposure to PAH, recent 
validation studies highlight urinary 1-hydroxy-
pyrene as a methodology already validated for 
monitoring exposure and PAH-DNA adducts in 
lymphocytes as a marker of effective dose. The 
most promising biomarkers still in the validation 
process include cytogenetic markers of early ef-
fect, evaluation of frequency of chromosomal ab-
errations, and micronucleus induction.
Future prospects for application of biomark-
ers to environmental risk assessment of PAH ex-
posure are promising. The expected advances for 
the coming years are: increased reliability in the 
exposure assessment and detection of early harm 
in populations exposed to low doses and to the 
mixture of chemical substances; increased sensi-
tivity of these studies for the identification of ge-
netic variations linked to chromosomal damage; 
reduction in the cost of molecular techniques; 
and increased use of automation.
Importantly, biomarkers represent key pros-
pects for expanding scientific research in the en-
vironmental health field. However, in the field of 
science as well, some barriers between areas of 
knowledge need to be eliminated in order to en-
sure the interdisciplinarity these studies require, 
especially in relation to the recognition of the en-
vironmental area as an important field in public 
health.
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Resumo
Os hidrocarbonetos policíclicos aromáticos (HPAs) 
estão amplamente distribuídos no ambiente e alguns 
são carcinogênicos para humanos. O estudo dos bio-
marcadores tem contribuído para a compreensão da 
natureza e magnitude dos riscos que estas substâncias 
representam à saúde humana. Este trabalho apresenta 
uma revisão do estado da arte dos biomarcadores de 
HPAs para avaliação de risco à saúde humana e ana-
lisa criticamente sua aplicabilidade, no contexto da 
gestão ambiental brasileira. Destaca as metodologias 
para a determinação de alguns biomarcadores como 
1-hidroxipireno e adutos HPA-DNA. Para avaliação do 
risco de câncer destacam-se marcadores citogenéticos, 
freqüência de aberrações cromossômicas e indução de 
micronúcleo. Também é abordado o estágio atual dos 
estudos de validação desses biomarcadores.
Hidrocarbonetos Policíclicos Aromáticos; Marcadores 
Biológicos; Avaliação de Risco
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